Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study
Hepatobiliary & Pancreatic Diseases International · 2023-12 · 22 (6) · 594-604
DOI: 10.1016/j.hbpd.2022.11.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hepatobiliary & Pancreatic Diseases International, 2023-12. Verfasst von Dan-Dan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; Shenzhen Institute of Advanced Technology…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although transarterial chemoembolization (TACE) is the first-line therapy for intermediate-stage hepatocellular carcinoma (HCC), it is not suitable for all patients. This study aimed to determine how to select patients who are not suitable for TACE as the first treatment choice. METHODS: A total of 243 intermediate-stage HCC patients treated with TACE at three centers were retrospectively enrolled, of which 171 were used for model training and 72 for testing. Radiomics features were screened using the Spearman correlation analysis and the least absolute shrinkage and selection operator (LASSO) algorithm. Subsequently, a radiomics model was established using extreme gradient boosting (XGBoost) with 5-fold cross-validation. The Shapley additive explanations (SHAP) method was used to visualize the radiomics model. A clinical model was constructed using univariate and multivariate logistic regression. The combined model comprising the radiomics signature and clinical factors was then established. This model's performance was evaluated by discrimination, calibration, and clinical application. Generalization ability was evaluated by the testing cohort. Finally, the model was used to analyze overall and progression-free survival of different groups. RESULTS: A third of the patients (81/243) were unsuitable for TACE treatment. The combined model had a high degree of accuracy as it identified TACE-unsuitable cases, at a sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of 0.759, 0.885, 0.906 [95% confidence interval (CI): 0.859-0.953] in the training cohort and 0.826, 0.776, and 0.894 (95% CI: 0.815-0.972) in the testing cohort, respectively. CONCLUSIONS: The high degree of accuracy of our clinical-radiomics model makes it clinically useful in identifying intermediate-stage HCC patients who are unsuitable for TACE treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
- Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
- Department of PET/CT, the First Affiliated Hospital of Harbin Medical University, Harbin 150007, China.
- Department of Interventional Therapy, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.
- Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China. Electronic address: jianghuijie@hrbmu.edu.cn.
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. Electronic address: fc.jia@siat.ac.cn.
Zitieren
APA
Wang, D. D., Zhang, J. F., Zhang, L. H., Niu, M., Jiang, H. J., Jia, F. C., & Feng, S. T. (2023). Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study. Hepatobiliary & Pancreatic Diseases International, 22(6), 594-604. https://doi.org/10.1016/j.hbpd.2022.11.005
Vancouver
Wang DD, Zhang JF, Zhang LH, Niu M, Jiang HJ, Jia FC, et al. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study. Hepatobiliary & Pancreatic Diseases International. 2023;22(6):594-604. doi:10.1016/j.hbpd.2022.11.005
BibTeX
@article{Wang2023,
author = {Wang, Dan-Dan and Zhang, Jin-Feng and Zhang, Lin-Han and Niu, Meng and Jiang, Hui-Jie and Jia, Fu-Cang and Feng, Shi-Ting},
title = {Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study},
journal = {Hepatobiliary & Pancreatic Diseases International},
year = {2023},
volume = {22},
number = {6},
pages = {594--604},
doi = {10.1016/j.hbpd.2022.11.005}
}
EUVIMED